Phase 1b/2 Trial of AVB-S6-500 for Platinum-resistant Recurrent OC Begins

Phase 1b/2 Trial of AVB-S6-500 for Platinum-resistant Recurrent OC Begins
The first part of a Phase 1b/2 trial evaluating the combination of Aravive Biologics’ investigational therapy AVB-S6-500 with standard-of-care therapies in patients with platinum-resistant recurrent ovarian cancer has begun treating patients. Patient enrollment is ongoing at several U.S. locations, with additional study sites yet to open. AVB-S6-500, Aravive’s lead treatment candidate, is intended to bind to a protein called Gas6 with high affinity, blocking activation of the GAS6-AXL signaling pathway by reducing or preventing the interaction of GAS6 with the AXL receptor. Elevated levels of GAS6 have been linked with metastasis, having a more aggressive cancer, treatment resistance, and poorer survival in people with advanced ovarian and breast cancer, and in people with acute myeloid leukemia. In a prior Phase 1 trial (NCT03401528) in 43 healthy volunteers, treatment with AVB-S6-500 was safe and well-tolerated, with neither serious adverse events nor dose-limiting adverse events being reported. Patients receiving increasing doses of the treatment exhibited a dose-dependent reduction in circulating free GAS6, also lasting longer with higher doses of the therapy. Also, the affinity
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *